PD-L1 (TAP) >= 5%
About
Biomarker type: Protein expression
Marker: PD-L1
Unit: Tumor Area Positivity (TAP)
Equality: >=
Value: 0.05
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Cisplatin, Fluorouracil, Tislelizumab | |
| EMA (1) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Capecitabine, Cisplatin, Tislelizumab | |
| EMA (1) HSE (1) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Fluorouracil, Oxaliplatin, Tislelizumab | |
| EMA (1) HSE (1) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Capecitabine, Oxaliplatin, Tislelizumab | |
| EMA (1) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Cisplatin, Paclitaxel, Tislelizumab | |
| EMA (1) | PD-L1 (TAP) >= 5% | Esophageal Squamous Cell Carcinoma | Oxaliplatin, Paclitaxel, Tislelizumab | |
| EMA (1) | PD-L1 (TAP) >= 5% | Adenocarcinoma of the Gastroesophageal Junction | Capecitabine, Oxaliplatin, Tislelizumab | |
| EMA (1) | PD-L1 (TAP) >= 5% | Adenocarcinoma of the Gastroesophageal Junction | Cisplatin, Fluorouracil, Tislelizumab |